Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27279544

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Jul
First author
Choueiri TK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):850-852. doi: 10.1016/S1470-2045(16)30175-9.
    note
    Source null
    related pmid
    27279543
    relationship
    Comment in
  2. citation
    Transl Androl Urol. 2016 Dec;5(6):974-976. doi: 10.21037/tau.2016.11.06.
    note
    Source null
    related pmid
    28078236
    relationship
    Comment in

Authors and identifiers

  1. name
    Choueiri TK
    type
    Author
  2. name
    Escudier B
    type
    Author
  3. name
    Powles T
    type
    Author
  4. name
    Tannir NM
    type
    Author
  5. name
    Mainwaring PN
    type
    Author
  6. name
    Rini BI
    type
    Author
  7. name
    Hammers HJ
    type
    Author
  8. name
    Donskov F
    type
    Author
  9. name
    Roth BJ
    type
    Author
  10. name
    Peltola K
    type
    Author
  11. name
    Lee JL
    type
    Author
  12. name
    Heng DYC
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Choueiri TK
    type
    Author
  2. name
    Escudier B
    type
    Author
  3. name
    Powles T
    type
    Author
  4. name
    Tannir NM
    type
    Author
  5. name
    Mainwaring PN
    type
    Author
  6. name
    Rini BI
    type
    Author
  7. name
    Hammers HJ
    type
    Author
  8. name
    Donskov F
    type
    Author
  9. name
    Roth BJ
    type
    Author
  10. name
    Peltola K
    type
    Author
  11. name
    Lee JL
    type
    Author
  12. name
    Heng DYC
    type
    Author
bibliography ids
  1. nci-bib-0f89f89834aa392a54cb175c
book metadata
content sha256
4ec981d3085a97b1cee009a37866b879eea1b43df457bdba5faa7f3b0cb21a29
document type
citation
dois
  1. 10.1016/S1470-2045(16)30107-3
electronic publication date
display
2016 Jun 5
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27279544
immutable id
pubmed:27279544@4ec981d3085a97b1cee009a37866b879eea1b43df457bdba5faa7f3b0cb21a29
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
917-927
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):850-852. doi: 10.1016/S1470-2045(16)30175-9.
    note
    Source null
    related pmid
    27279543
    relationship
    Comment in
  2. citation
    Transl Androl Urol. 2016 Dec;5(6):974-976. doi: 10.21037/tau.2016.11.06.
    note
    Source null
    related pmid
    28078236
    relationship
    Comment in
outcomes validated
false
pmid
27279544
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
57d4fa165f334721df81ed2735aa7ab41b0a4d514a480b15f3f1638705dbbd18
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Jul
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27279544/
title
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice